Skip to main content
SpringerLink
Log in

Obesity and Dyslipidemia

  • Review
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This article sumarizes pathopysiological consequencies between obesity and dyslipidemia and aims to bring some practical approach.

Recent Findings

Dyslipidemia is often present in individuals with obesity and simultaneusly, many obese individuals have lipid metabolism disorders. Especially the abdominal obesity increases the cardiometabolic risk because of the presence of atherogenic dyslipidemia while the total low density lipoprotein cholesterol (LDL-C) may be normal. LDL-C is the primary goal in dyslipidemia treatment. Apoliprotein B (Apo B) and non – high density lipoprotein cholesterol (non-HDL-C) should be estimated to precise the cardiovascular risk and represents the secondary goal in treatment. Weight loss either with diet or antiobestic medication induces the decrease in triglycerides (TG) and LDL-C and the increase in HDL-C. Composition of nutrients, esp. fatty acids, influences lipid levels. Bariatric surgery is efficient in weight loss and has a significant effect on serum lipids.

Summary

Dyslipidemia and obesity present common diseases that must be managed to decrease the cardiovascular risk and the risk of obesity-related complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. https://www.who.int/health-topics/obesity. Accessed August 13, 2023.

  2. Fryar CD, Carroll MD, Afful J. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018. NCHS Health E-Stats, Centers for Disease Control and Prevention. 2020. Updated February 8, 2021. Accessed January 29, 2021. https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/obesity-adult.htm.

  3. WHO EUROPEAN REGIONAL OBESITY REPORT 2022. ISBN: 978–92–890–5773–8. World Health Organization 2022. https://www.who.int/europe/publications/i/item/9789289057738.

  4. • Adult overweight causes and consequences. Centers for Disease Control and Prevention. Updated March 22, 2021. Accessed January 29, 2021. www.cdc.gov/obesity/basics/causes.html. A systhematic review with a new insight on overweight/obesity.

  5. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–64. https://doi.org/10.1053/j.gastro.2020.01.052.

    Article  CAS  PubMed  Google Scholar 

  6. • Vekic J, Stefanovic A, Zeljkovic A. Obesity and Dyslipidemia: A Review of Current Evidence. Curr Obes Rep. 2023. https://doi.org/10.1007/s13679-023-00518-z. A systhematic review with a new insight on atherogenic dyslipidemia and obesity.

    Article  PubMed  Google Scholar 

  7. Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. Diabetes. 2016;65:1767–78. https://doi.org/10.2337/db16-0046.

    Article  CAS  PubMed  Google Scholar 

  8. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89:2595–600. https://doi.org/10.1210/jc.2004-0372.

    Article  CAS  PubMed  Google Scholar 

  9. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KI, Fruchart JK, James WPT, Loria CM, SmithJr SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.

    Article  CAS  PubMed  Google Scholar 

  10. Cornier MA. A Review of Current Guidelines for the Treatment of Obesity. Am J Manag Care. 2022;28(suppl 15):S288–96. https://doi.org/10.37765/ajmc.2022.89292.

    Article  PubMed  Google Scholar 

  11. Garvey WT, Mechanick JI, Brett EM, et al. Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(suppl 3):1–203. https://doi.org/10.4158/EP161365.GL.

    Article  PubMed  Google Scholar 

  12. Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, BerryJD, Das SR, Vega GL, Khera A, McGuire DK, Grundy SM, de LemosJA. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring) 2013:21(9):E439–47. https://doi.org/10.1002/oby.20135.

  13. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology Genetics, and Biology. Circ Res. 2016;18(4):547–63. https://doi.org/10.1161/CIRCRESAHA.115.306249.

    Article  CAS  Google Scholar 

  14. • Balling M, Afzal S, Smith SD, Varbo A, Langsted A, Kamstrup PR, Nordestgaard BG. Elevated LDL Triglycerides and Atherosclerotic Risk. Am Coll Cardiol. 2023;81(2):136–52. https://doi.org/10.1016/j.jacc.2022.10.019. Important notes on LDL-TG.

    Article  CAS  Google Scholar 

  15. • Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart J. 2021;42:3227–337. https://doi.org/10.1093/eurheartj/ehab484. The newest cardiovascular prevention guidelines.

  16. Arnett D, Blumenthal R, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Dennison Himmelfarb C, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Virani SS, Williams KA, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol. 2019;74(10):e177–232. https://doi.org/10.1016/j.jacc.2019.03.010.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Petridou A, Siopi A, Mougios V. Exercise in the management of obesity. Metabolism. 2019;92:163–9. https://doi.org/10.1016/j.metabol.2018.10.009.

    Article  CAS  PubMed  Google Scholar 

  18. Ahmed HM, Blaha MJ, Nasir K, Rivera JJ, Blumenthal RS. Effects of physical activity on cardiovascular disease. Am J Cardiol. 2012;109:288–95. https://doi.org/10.1016/j.amjcard.2011.08.042.

    Article  PubMed  Google Scholar 

  19. Sarzynski MA, Burton J, Rankinen T, Blair SN, Church TS, Despres JP, Hagberg JM, Landers-Ramos R, Leon AS, Mikus CR, Rao DC, Seip RL, Skinner JS, Slentz CA, Thompson PD, Wilund KR, Kraus WE, Bouchard C. The effects of exercise on the lipoprotein subclass profile: A meta-analysis of 10 interventions. Atherosclerosis. 2015;243:364–72. https://doi.org/10.1016/j.atherosclerosis.2015.10.018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Doewes RI, Gharibian G, Zadeh FA, Zaman BA, Vahdat S, Akhavan-Sigari R. An Updated Systematic Review on the Effects of Aerobic Exercise on Human Blood Lipid Profile. Curr Probl Cardiol. 2023;48(5):101108. https://doi.org/10.1016/j.cpcardiol.2022.101108.

    Article  PubMed  Google Scholar 

  21. Kraus WE, Powell KE, Haskell WL, Janz KF, Campbell WW, Jakicic JM, Troiano RP, Sprow K, Torres A, Piercy KL. 2018 Physical Activity Guidelines Advisory Committee. Physical Activity, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease. Med Sci Sports Exerc. 2019;51:1270–81. https://doi.org/10.1249/MSS.0000000000001939.

  22. Hasan B, Nayfeh T, Alzuabi M, Wang Z, Kuchkuntla AR, Prokop LJ, Newman CB, Murad MH, Rajjo TI. Weight Loss and Serum Lipids in Overweight and Obese Adults: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2020;105(12):dgaa673. https://doi.org/10.1210/clinem/dgaa673.

  23. Feingold KR, Anawalt B, Blackman MR, et al. editors. South Dartmouth (MA): MDText.com, Inc. 2000.

  24. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E, Williamson DA. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859–73. https://doi.org/10.1056/NEJMoa0804748.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bueno NB, de Melo IS, de Oliveira SL, da Rocha Ataide T. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr. 2013;110:1178–87. https://doi.org/10.1017/S0007114513000548.

    Article  CAS  PubMed  Google Scholar 

  26. Mozaffarian D. Natural trans fat, dairy fat, partially hydrogenated oils, and cardiometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study. Eur Heart J. 2016;37(13):1079–81. https://doi.org/10.1093/eurheartj/ehv595.

    Article  PubMed  Google Scholar 

  27. Chen M, Li Y, Sun Q, Pan A, Manson JE, Rexrode KM, Willett WC, Rimm EB, Hu FB. Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults. Am J Clin Nutr. 2016;104(5):1209–17. https://doi.org/10.3945/ajcn.116.134460.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Islam MA, Amin MN, Siddiqui SA, Hossain MP, Sultana F, Kabir MR. Trans fatty acids and lipid profile: A serious risk factor to cardiovascular disease, cancer and diabetes. Diabetes Metab Syndr. 2019;13(2):1643–7. https://doi.org/10.1016/j.dsx.2019.03.033.

    Article  PubMed  Google Scholar 

  29. • Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), European Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455. The newest guidelines on dyslipidemia.

  30. Sahle BW, Chen W, Rawal LB, Renzaho MN. JAMA Netw Open. 2021;4(4):e217044. https://doi.org/10.1001/jamanetworkopen.2021.7044.

  31. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study Group. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920–2. https://doi.org/10.2337/dc09-1825.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Pekgor S, Duran C, Marakoglu K, Solak I, Pekgor A, Eryilmaz MA. The Effects of Smoking Cessation on Visceral Adiposity Index Levels. Niger J Clin Pract. 2018;21(6):743–51. https://doi.org/10.4103/njcp.njcp_245_17.

    Article  CAS  PubMed  Google Scholar 

  33. Behl TA, Stamford BA, Moffatt RJ. The Effects of Smoking on the Diagnostic Characteristics of Metabolic Syndrome: A Review. Am J Lifestyle Med. 2022;17(3):397–412. https://doi.org/10.1177/15598276221111046.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Heffron SP, Parikh A, Volodarskiy A, Ren-Fielding C, Schwartzbard A, Nicholson J, Bangalore S. Changes in Lipid Profile of Obese Patients Following Contemporary Bariatric Surgery: A Meta-Analysis. Am J Med. 2016;129(9):952–9. https://doi.org/10.1016/j.amjmed.2016.02.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330–42. https://doi.org/10.1038/oby.2011.330.

    Article  CAS  PubMed  Google Scholar 

  36. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52. https://doi.org/10.1016/S0140-6736(11)60205-5.

    Article  CAS  PubMed  Google Scholar 

  37. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308. https://doi.org/10.3945/ajcn.111.024927.

    Article  CAS  PubMed  Google Scholar 

  38. Sahebkar A, Simental-Mendía LE, Reiner Ž, Kovanen PT, Simental-Mendía M, Bianconi V, Pirro M. Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. Pharmacol Res. 2017;122:53–65. https://doi.org/10.1016/j.phrs.2017.05.022.

    Article  CAS  PubMed  Google Scholar 

  39. Nakou ES, Filippatos TD, Georgoula M, Kiortsis DN, Tselepis AD, Mikhailidis DP, Elisaf MS. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin. 2008;24:1919–29. https://doi.org/10.1185/03007990802177150.

    Article  CAS  PubMed  Google Scholar 

  40. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O’Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19:110–20. https://doi.org/10.1038/oby.2010.147.

    Article  CAS  PubMed  Google Scholar 

  41. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E, Group C-IS. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935–43. https://doi.org/10.1002/oby.20309.

    Article  CAS  PubMed  Google Scholar 

  42. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP, Obesity S, Prediabetes NNSG. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015;373:11–22. https://doi.org/10.1056/NEJMoa1411892

  43. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O’Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT, Investigators S. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325:1403–13. https://doi.org/10.1001/jama.2021.1831.

    Article  CAS  PubMed  Google Scholar 

  44. Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis. 2013;23(9):799–807. https://doi.org/10.1016/j.numecd.2013.05.002.

    Article  CAS  PubMed  Google Scholar 

  45. Sharma A, Joshi PH, Rinehart S, Thakker KM, Lele A, Voros S. Baseline very low-density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibric acid, or their combination in patients with mixed dyslipidemia. J Cardiovasc Transl Res. 2014;7(4):465–74. https://doi.org/10.1007/s12265-014-9559-3.

    Article  PubMed  Google Scholar 

  46. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–61. https://doi.org/10.1016/S0140-6736(16)31357-5.

    Article  CAS  PubMed  Google Scholar 

  47. Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN, Chilcott J. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009;265(5):568–80. https://doi.org/10.1111/j.1365-2796.2008.02062.x.

    Article  CAS  PubMed  Google Scholar 

  48. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387–97. https://doi.org/10.1056/NEJMoa1410489.

  49. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, Park JG, White JA, Bohula EA, Braunwald E; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571–82. https://doi.org/10.1161/CIRCULATIONAHA.117.030950.

  50. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126(3):314–45. https://doi.org/10.1016/j.pharmthera.2010.01.008.

    Article  CAS  PubMed  Google Scholar 

  51. • Kim NH, Kim SG. Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction. Diabetes Metab J. 2020;44(2):213–21. https://doi.org/10.4093/dmj.2020.0001. A brief review on fibrates in atherogenic dyslipidemia.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. https://doi.org/10.1056/NEJMoa1812792.

  53. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;4(4):CD011748. https://doi.org/10.1002/14651858.CD011748.pub2. Update in: Cochrane Database Syst Rev. 2020 Oct 20:10:CD011748.

  54. Stein EA, Turner TA. Are the PCSK9 inhibitors the panacea of atherosclerosis treatment? Expert Rev Cardiovasc Ther. 2017;15(7):491–4. https://doi.org/10.1080/14779072.2017.1348231.

    Article  CAS  PubMed  Google Scholar 

  55. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507–19. https://doi.org/10.1056/NEJMoa1912387.

  56. Pirillo A, Catapano AL. New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes. 2022;29(2):161–6. https://doi.org/10.1097/MED.0000000000000706%3e.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Non-financially supported by the Charles University Research programme „Cooperatio – Cardiovascular Science “.

Author information

Authors and Affiliations

  1. 2nd Medical Department, Chales University, Faculty of Medicine in Pilsen, alej Svobody 76, Plzen (Pilsen), 323 00, Czech Republic

    Barbora Nussbaumerova & Hana Rosolova

Authors
  1. Barbora Nussbaumerova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hana Rosolova
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

B.N. wrote cca 2/3 of the main manusript and prepaired the table. H.R. wrote cca 1/3 of the main manusript. Both authors reviewed the manuscript.

Corresponding author

Correspondence to Barbora Nussbaumerova.

Ethics declarations

Informed Consent

No informed consent needed.

Conflict of Interest

The authors have no financial interests that are directly or indirectly related to the work submitted for publication. They do not have any competing interrests. The work was supported non-financially by the Charles University Research programme „Cooperatio – Cardiovascular Science “.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nussbaumerova, B., Rosolova, H. Obesity and Dyslipidemia. Curr Atheroscler Rep 25, 947–955 (2023). https://doi.org/10.1007/s11883-023-01167-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-023-01167-2

Keywords

Search

Navigation